Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China

Original Submission
3 May 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
9 Aug 2022 Reviewed Reviewer Report
12 Sep 2022 Reviewed Reviewer Report - Marjolijn Van Keep
26 Sep 2022 Author responded Author comments - Xiaoling Wang
Resubmission - Version 3
26 Sep 2022 Submitted Manuscript version 3
6 Oct 2022 Reviewed Reviewer Report - Marjolijn Van Keep
21 Oct 2022 Reviewed Reviewer Report
9 Nov 2022 Author responded Author comments - Xiaoling Wang
Resubmission - Version 4
9 Nov 2022 Submitted Manuscript version 4
11 Nov 2022 Reviewed Reviewer Report - Marjolijn Van Keep
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
14 Dec 2022 Editorially accepted
26 Dec 2022 Article published 10.1186/s12913-022-08971-7

You can find further information about peer review here.

Back to article page